跳至主要内容
临床试验/NCT05632744
NCT05632744已完成不适用

Evaluation of CG-100 Intraluminal Bypass Device

Colospan Ltd.2 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2023年3月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Colospan Ltd.
入组人数
7
试验地点
2
主要终点
Safety of the CG-100 Intraluminal Bypass Device

研究概览

简要总结

Evaluation of CG-100 Intraluminal Bypass device

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • (pre-operative):
  • Willing to comply with protocol-specified follow-up evaluations
  • 22-75 (inclusive) years of age at screening
  • Diagnosed with colorectal cancer
  • Has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent

排除标准

  • 未提供

研究组 & 干预措施

CG-100 Intraluminal Bypass Device

Experimental

Subjects will be treated with CG-100 Intraluminal Bypass Device

干预措施: CG-100 Intraluminal Bypass Device (Device)

结局指标

主要结局

Safety of the CG-100 Intraluminal Bypass Device

时间窗: 10 days

Assessment of Serious Adverse Events

次要结局

  • Safety of the CG-100 Intraluminal Bypass Device(4 weeks)

研究者

发起方
Colospan Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验